The discovery 50 years ago of the spectacular efficacy of L-DOPA has revolutionized the treatment of Parkinson disease (PD), and indeed all modern Clinical Pharmacology. However, within a few years, PD patients on chronic L-DOPA therapy almost inevitably face disabling periods of reduced benefit, known as motor and non-motor “fluctuations” 1. In 2016, adequate management…